Results 191 to 200 of about 117,497 (280)

The <i>NFIA::CBFA2T3</i> identifies a molecularly defined subgroup of acute erythroid leukemia/erythroid sarcoma. [PDF]

Front Oncol
Brunetti M, Andersen K, Tjønnfjord GE, Zeller B, Spetalen S, Munthe-Kaas MC, Osnes LTN, Os TT, Micci F.   +8 more
europepmc   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

A new c.681dup RUNX1 variant in familial leukemia. [PDF]

Fam Cancer
Crocioni M, Nardelli C, Lema Fernandez AG, Bardelli V, Pierini V, Matteucci C, Beggiato E, Olivi M, Vigliani V, Pelle A, Lanzarone G, Mecucci C.   +11 more
europepmc   +1 more source

CDK6 inactivation counteracts CALR‐mutant‐induced MPN evolution and sensitizes MPN stem cells to interferon‐α treatment

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Interferon‐α (IFNα) remains a potent therapeutic option for myeloproliferative neoplasms (MPNs) with an activated JAK/STAT signaling axis. However, variable patient responses highlight the need for optimized combination strategies. Recent studies suggest a link between cyclin‐dependent kinase 6 (CDK6) and IFN signaling.
Brian Ringhofer, Wolfram Polzer, Michaela Prchal‐Murphy, Eszter Doma, Sebastian Kollmann, Elisabeth Gamper, Jonatan Kendler, Belinda S. Maw, Eva Zebedin‐Brandl, Juan Li, Anthony R. Green, Maria‐Theresa Krauth, Emir Hadzijusufovic, Daniel Ivanov, Peter Valent, Gregor Hoermann, Thorsten Klampfl, Veronika Sexl, Karoline Kollmann   +18 more
wiley   +1 more source

ILC2s and their immune checkpoints in the antitumor response. [PDF]

J Immunother Cancer
Ciancaglini C, Santopolo S, Vacca P, Moretta L, Quatrini L.   +4 more
europepmc   +1 more source

SNARE motif-mediated sorting of synaptobrevin by the endocytic adaptors clathrin assembly lymphoid myeloid leukemia (CALM) and AP180 at synapses

Proceedings of the National Academy of Sciences of the United States of America, 2011
S. Koo, S. Marković, D. Puchkov, Carsten C. Mahrenholz, Figen Beceren-Braun, Tanja Maritzen, J. Dernedde, R. Volkmer, H. Oschkinat, V. Haucke   +9 more
semanticscholar   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

LC3 gene expression as a marker of autophagy in acute myeloid and lymphoblastic leukemia: a systematic review. [PDF]

Discov Oncol
Kiani R, Taheri H, Hatami A, Dastghaib S, Safari F, Mokaram P.   +5 more
europepmc   +1 more source

Efferocytosis: Signaling Pathways and New Therapeutic Strategies for Diseases

MedComm, Volume 7, Issue 5, May 2026.
1. Efferocytosis coordinates molecular signaling and metabolic reprogramming to resolve inflammation. 2. Efferocytosis dysfunction underlies four conserved pathological hallmarks across diseases. 3. Therapeutic strategies targeting efferocytosis should be context‐dependent: enhance or inhibit based on disease type. ABSTRACT Efferocytosis—the phagocytic
Lei Wang, Jingjing Ge, Zehua Wang, Yihua Fang, Yongxu Jia, Ruyue Zhang, Yanru Qin   +6 more
wiley   +1 more source

Concomitant Clonal <i>CBFB</i>::<i>MYH11</i> and <i>PDGFRB</i> Fusions in a Case of <i>De Novo</i> Acute Myeloid Leukemia. [PDF]

Hematol Rep
Ding Q, Lewis NE, Artymiuk CJ, Olson RM, He R, Ketterling RP, Viswanatha DS, Greipp PT, Zepeda Mendoza CJ.   +8 more
europepmc   +1 more source